ISRCTN11659633进行中（未招募）1 期
A phase I, randomized, double-blind, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 following single and multiple doses in healthy participants and open-label cohorts in participants with autoimmune diseases
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 11/03/2024:
- •Participants between the ages of 18 and 75 years old will be included.
- •Previous participant inclusion criteria:
- •1. Have a body weight of =50 kg
- •2. Are willing and capable of giving written informed consent, which includes being able to comply with all aspects of the study treatment and testing schedule
- •3. Have adequate venous access, assessed at the time of screening, that allows for IV dosing and/or repeated phlebotomy
- •4. Are healthy as determined by the Investigator based on a medical evaluation including medical history, physical examination, laboratory tests, and Electrocardiogram (ECG).
- •5. Are female, not lactating, and of NCBP
- •6. Are male and have had a vasectomy >6 months prior to the Screening Visit or agree to use contraceptive methods starting at the Screening Visit and continuing throughout the study and for 90 days after the final study treatment administration
排除标准
- •Current participant exclusion criteria as of 11/03/2024:
- •Not meeting the inclusion criteria.
- •Previous participant exclusion criteria:
- •1. Have any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as judged by the Investigator.
- •2. Have an active malignancy or history of malignancy in the 3 years prior to the Screening Visit (exclusive of non-melanoma skin cancer, cervical cancer in situ or prostate cancer in situ) or any history of malignancy not deemed cured by adequate treatment.
- •3. Have any clinically significant history of allergic conditions, including drug allergies, anaphylactic reactions, or hypersensitivity to study treatments or components. Participants with currently asymptomatic, seasonal allergies or exercise-induced bronchospasm prior to study treatment administration are eligible.
- •4. Have undergone any blood loss or phlebotomy with removal of =500 milliliter (mL) of blood within 56 days prior to the Screening Visit.
- •5. Have received a transfusion of any blood or blood products within 56 days or donated plasma within 7 days prior to the Screening Visit.
- •6. Have participated in any other study involving an investigational product (IP) within the last 30 days or 5 half-lives, whichever is greater, (6 months for anti-neonatal fragment crystallizable receptor [FcRn] therapy), prior to the Screening Visit or during the study.
研究者
相似试验
Unknown
1 期
A phase I clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjectsCTRI/2012/05/002691Piramal Healthcare Limited96
招募中
不适用
A phase I, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of GDC-6599 and the effect of food on the pharmacokinetics and pharmacodynamics of GDC-6599 in healthy adult subjectsAsthma10024970NL-OMON52277Genentech, Inc.92
招募中
1 期
Phase I Single-Administration Study of TKT001-SHealthy adult malesJPRN-jRCT2071230046Kai Megumi16
已完成
不适用
A phase I, double-blind, randomized, placebo-controlled, multicenter, Single- and multiple-ascending-dose study to determine initial safety, Tolerability, and pharmacokinetics of GDC-0134 in patients with amyotrophic Lateral sclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON46547Genentech, Inc.6
已完成
1 期
A study to evaluate the safety, tolerability, processing by the body, and response of the body to the drug VK2735 in healthy adultson-alcoholic steatohepatitis (NASH)Digestive SystemOther specified inflammatory liver diseasesISRCTN47896018Viking Therapeutics, Inc.88